Closed-loop Control of Glucose Levels (Artificial Pancreas) for 12 Days in Adults With Type 1 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 24, 2019

Primary Completion Date

January 27, 2020

Study Completion Date

January 27, 2020

Conditions
Type 1 Diabetes
Interventions
OTHER

12-day intervention with sensor-augmented pump therapy

"A sensor will be inserted on the day before the start of the intervention by the participants. The participant will also have to install the study insulin pump. Participants will be advised to continue with study intervention at home for the next 12 days.~Participants will have been previously shown how to use the study insulin pump."

OTHER

12-day intervention with single-hormone closed-loop strategy

"A sensor will be inserted on the day before the start of the intervention by the participants. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given.~Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 12 days."

DEVICE

Insulin pump

Tandem Diabetes Care

DEVICE

Continuous glucose monitoring system

Dexcom G5 Platinum

DRUG

Insulin

Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)

Trial Locations (2)

H2W 1R7

Institut de recherches cliniques de Montréal, Montreal

H4A 3J1

McGill University Health Centre, Montreal

All Listed Sponsors
lead

Institut de Recherches Cliniques de Montreal

OTHER

NCT02846831 - Closed-loop Control of Glucose Levels (Artificial Pancreas) for 12 Days in Adults With Type 1 Diabetes | Biotech Hunter | Biotech Hunter